EXCITING—The Novavax protein-based #COVID vaccine has been authorized as a booster for adults ages 18 and older. People who got Pfizer, Moderna or J&J can now also receive #Novavax as a #booster! Also has benefit against #BA5. Cuts another anti-vax excuse. cnbc.com/2022/10/19/fda…

Causes of #coagulation abnormalities in adults is the focus of today's #EHA #ThinkingThursday: can you fill in the missing parts A, B and C? Share your answer with us in the comments below.

Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Carlos E. Vigil, MD,MS Talha Badar Agree all frontline comparisons in older/unfit AML should be against AZA+VEN. We don’t need another 10 years of chlorambucil bashing if you get my drift 😀 Musa Yilmaz, MD Nicholas Short MD Jessica Altman, MD Eunice Wang MD Daniel Pollyea

👉👉👉New paper alert 🚨from our group ➡️ Ph2 Led by Dr Nitin Jain Nitin Jain | Bill Wierda, MD, PhD Jayastu Senapati Tapan Kadia Naval Daver, M.D. Gautam Borthakur Marina Konopleva Naveen Pemmaraju, MD Joseph D. Khoury, MD, FCAP Hagop Kantarjian,MD @PamSharmaMDPhD @JimAllisonPhD pubmed.ncbi.nlm.nih.gov/36287248/ | #leusm #ImmunoOnc #endcancer

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients | Leukemia nature.com/articles/s4137…

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes - PubMed pubmed.ncbi.nlm.nih.gov/36309981/

What’s going on with the international #FludarabineShortage? In this perspective article, authors go over issues impacting transplantation & immune effector #celltherapy delivery. Read more: ow.ly/2NYZ50LtIx6

Epcor + R2 looking extremely active in R/R FL. ORR 100% with 96% CMR. Not necessarily very high risk group but even so impressive. Tox as expected - v little toci use. #ESHLymphoma22 #lymsm

CD19 CAR T cells from India at 35,000 $ >>> Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India nature.com/articles/s4140… #lymsm

I make one mistake and I’m on thin ice….I was trying to be healthy by reheating Salmon from the night before and now I may never graduate from interventional fellowship.

Is it game over after CAR-T fails in #DLBCL. Mounting evidence suggests that old treatments (allo) still important in salvaging a responding subset. More evidence by stars in MCW Hematology & Oncology team Fateeha Furqan Nirav Shah Tim Fenske #alloHCT #bmtsm #lymsm pubmed.ncbi.nlm.nih.gov/36417762/

Upfront autologous stem cell transplantation more than doubled the rate of minimal residual disease (MRD) negativity in patients with newly diagnosed multiple myeloma. Read the full article: astctjournal.org/article/S2666-… #Lymsm

Impending cytopenia (they were going down). #mASHcots #ASH22

Terrific presentation at #ASH22 #BMTsm session on the role of #abatacept plus CNI/MTX as #GVHD prophylaxis in 7/8 or 8/8 UD transplant. Time to change our standard of care? ASH

E. Donnal Thomas Award to Dr Bruce Blazar at #ash2022. Congratulations to a giant of transplant immunology ⁦ASTCT⁩ ⁦@BldCancerDoc⁩ ⁦ASH⁩

Blazar delivering his ED Thomas lecture at #ASH22 is a masterful description of scientific rigour, advancing knowledge and persistence in the face of failure to improve overall clinical outcomes. So far. #GVHD versus #GVL remains a challenge.

No one could do a better job of explaining the complexity of p53 than @ColemanLindsley #ASH22

Joshua Zeidner MD Totally agree. Is VEN adding anything in TP53m beyond AZA+Magro. Hopefully we can answer this with more mature data from the ongoing magro phase 3s….